A new drug has been cleared for human trials in patients with anaplastic astrocytoma and glioblastoma brain cancers. The drug, PAC-1, is reported to spur cancer cells to self destruct and has proven to be effective in animal models of brain cancers.
Cannabidiol (CBD) appears to slow the growth of glioblastoma brain cancer cells in both animal and human cell lines. CBD's anti-cancer actions target mitochondria, causing them to dysfunction and release harmful reactive oxygen species. Cancer cells treated with CBD exhibited significant decreases in mitochondrial activity.
A new Baylor study reveals the CD44s molecule gives glioblastoma brain cancer cells a survival advantage. Removing CD44s from cancer cells and treating with erlotinib helped to promote the death of cancer cells than by just treating the cancer with erlotinib alone, researchers said.
Researchers report the addition of an FDA approved chemotherapy drug called hydroxyyurea to temozolomide helps to increase survival rates in animal models of glioblastoma.
UCLA researchers report erlotinib, an FDA approved drug, reduces glucose uptake in glioblastoma, effectively cutting off nutrients and energy supply to the tumor.
Researchers are developing nanocarriers that are twice as effective as liposomes at reaching glioblastoma brain tumors.
Researchers detail the use of a drug that may help block the way glioblastoma brain cancer cells respond to fluid flow. The finding could lead to stopping glioblastoma from spreading.
Researchers have identified specific proteins that drive the development of cancer stem cells. They report targeting and suppressing galectin1, in addition to radiation therapy, could be an effective treatment for glioblastoma brain cancer.